Evidence map›Paper›PMID 42033315›Full record

ReviewSleep2026

Perspective-weight loss, obstructive sleep apnea therapy, or both for cardiometabolic risk in obesity-related obstructive sleep apnea?

Brandon Nokes, Brian S Wojeck, Christopher N Schmickl

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Sleep, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Sleep and obesity-known interactions and open questions.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Brandon NokesDepartment of Medicine, Sleep Medicine Section, VA San Diego Healthcare System, San Diego, CA, United States.ORCID 0000-0002-0436-7411
Brian S WojeckDepartment of Endocrinology, Yale University, New Haven, CT, United States.ORCID 0000-0001-9771-1332
Christopher N SchmicklDepartment of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of California at San Diego, La Jolla, CA, United States.ORCID 0000-0001-5417-9980

Funding

Acetazolamide to Improve Clinically Important Outcomes in Obstructive Sleep Apnea Patients with a High Loop Gain EndotypeK23HL161336 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Christopher Nikolaus Schmickl · 2022 to 2026
$863k
American Heart Association 26BCDA1622745CSRD VA IK2 CX002524NHLBI NIH HHS K23 HL161336NIH HHS K23HL161336NIH Loan Repayment ProgramVAVA IK2CX002524-01A2
6 · The paper itself

Abstract

The emergence of potent and durable obesity pharmacotherapies has the potential to drastically alter the treatment landscape for comorbid obesity and obstructive sleep apnea. Recent clinical trials examining the impact of weight loss on obstructive sleep apnea have demonstrated marked improvements in both weight and obstructive sleep apnea severity, leading to the first Food and Drug Administration approval of a weight loss medication for obstructive sleep apnea. However, several questions remain unanswered regarding which trial and management strategies will best optimize real-world outcomes for patients with comorbid obesity and obstructive sleep apnea in an equitable manner.

Indexed as

ObesitySleep Apnea, ObstructiveWeight LossAnti-Obesity AgentsCardiometabolic Risk FactorsHumansAnti-Obesity Agentsclinical trials researchobesityobstructive sleep apnea

Identifiers

PMID42033315
PMCPMC13357492

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.